Literature DB >> 35137341

Changing profile of platelet activity and turnover indices during treatment response of immune thrombocytopenia.

Chewei Ou1, Hung Chang2,3,4, Yu-Shin Hung5,1,6, Ming-Chung Kuo5,1, Pei-Ling Li5, Tung-Liang Lin5,1.   

Abstract

Both platelet count and function change after treatment of immune thrombocytopenia. Platelet function can be measured by plasma markers, including platelet activity [e.g., soluble P-selectin (sP-selectin) and soluble CD40 ligand (sCD40L)] and platelet turnover markers [e.g., glycocalicin (GC)]. Patients were classified into no response (NR, including new diagnosis), partial response (PR) and complete response (CR). One hundred and sixteen samples (29 CR, 32 PR, 55 NR) from 79 patients were collected. Plasma markers (sP-selectin, sCD40L and GC) were measured by ELISA. Platelet counts and mean platelet volume (MPV) were obtained in the clinical laboratory using GenS System-2. The results showed that responsive patients (PR + CR) had higher levels of sP-selectin (P = 0.026) and sCD40L (P = 0.001). Although there was no difference in MPV (P = 0.077) or GC (P = 0.078), there was a marked decrease of GC index (P < 0.001) in responsive patients. Paired sample analysis showed no difference in sP-selectin, sCD40L, MPV or GC but significant difference in GC index (P = 0.017) between NR and PR. Another paired sample analysis showed no difference in sP-selectin, sCD40L, MPV or GC but significant difference in GC index (P = 0.029) between PR and CR. Patients with refractory and newly diagnosed disease had a significant difference in GC (P = 0.020) and sCD40L (P = 0.001), despite similarly low platelet counts. In conclusion, platelet activity markers (sP-selectin and sCD40L) and GC indices change in parallel with treatment response. Plasma levels of GC and sCD40L may be predictors of treatment response.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  CD40 ligand; Glycocalicin; Immune thrombocytopenia; P-selectin

Year:  2022        PMID: 35137341     DOI: 10.1007/s10238-022-00790-8

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   5.057


  17 in total

1.  Evaluation of platelet function in thrombocytopenia.

Authors:  Mette Tiedemann Skipper; Peter Rubak; Jesper Stentoft; Anne-Mette Hvas; Ole Halfdan Larsen
Journal:  Platelets       Date:  2017-04-14       Impact factor: 3.862

2.  Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura.

Authors:  H Louwes; O A Zeinali Lathori; E Vellenga; J T de Wolf
Journal:  Am J Med       Date:  1999-04       Impact factor: 4.965

3.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

4.  Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.

Authors:  Hanny Al-Samkari; Elizabeth M Van Cott; David J Kuter
Journal:  Ann Hematol       Date:  2018-11-17       Impact factor: 3.673

5.  Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia.

Authors:  Simon Panzer; Lisa Höcker; Rainer Vormittag; Miriam Rieger; Daniela Koren; Daniela Dunkler; Ingrid Pabinger
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

6.  Platelet function in adult ITP patients can be either increased or decreased, compared to healthy controls, and is associated with bleeding risk.

Authors:  Rutger A Middelburg; Jannemieke C Carbaat-Ham; Husna Hesam; Max A A D Ragusi; Jaap Jan Zwaginga
Journal:  Hematology       Date:  2016-05-09       Impact factor: 2.269

7.  Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia.

Authors:  Y Kurata; S Hayashi; T Kiyoi; S Kosugi; H Kashiwagi; S Honda; Y Tomiyama
Journal:  Am J Clin Pathol       Date:  2001-05       Impact factor: 2.493

8.  Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.

Authors:  Anja J Gerrits; Emily A Leven; Andrew L Frelinger; Sophie L Brigstocke; Michelle A Berny-Lang; W Beau Mitchell; Shoshana Revel-Vilk; Hannah Tamary; Sabrina L Carmichael; Marc R Barnard; Alan D Michelson; James B Bussel
Journal:  Blood       Date:  2015-07-29       Impact factor: 22.113

9.  Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia.

Authors:  S Panzer; M Rieger; R Vormittag; B Eichelberger; D Dunkler; I Pabinger
Journal:  Eur J Clin Invest       Date:  2007-08-28       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.